Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

MAKING ANY MAJOR DIETARY CHANGES. THE WHITE HOUSE ANNOUNCING THIS WEEK A NEW DEAL TO MAKE WEIGHT LOSS MEDICATIONS SUCH AS WEGOVY AND ZEPBOUND MORE AFFORDABLE FOR MILLIONS OF AMERICANS. SO JOINING US ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral GLP-1 pill being studied for the treatment of type 2 diabetes and obesity, ...

Ozempic, which is injected once a week under careful medical supervision, is said to help control diabetes and help Type 2 ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient ...

(CNN) — Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity ...